Endure Biotherapeutics is pioneering the development of engineered, engraftable live biotherapeutics aimed at treating genetic and chronic diseases. Their innovative platform focuses on creating therapeutic bacterial strains that can persist in the gastrointestinal tract, distinguishing them from other microbiome companies. By isolating native bacteria from healthy individuals, the company employs molecular biology techniques to genetically modify these strains to deliver therapeutic proteins that are deficient or dysfunctional in patients. The resulting bioengineered live biotherapeutics are administered as oral capsules containing freeze-dried bacteria, which have shown promising results in early-stage mouse studies, demonstrating their ability to colonize various segments of the gastrointestinal tract and potentially cure conditions such as metabolic diseases and inflammatory bowel diseases.

The technology developed by Endure Biotherapeutics leverages native Escherichia coli as a chassis for transgene delivery, allowing for persistent physiological changes in conventionally-raised hosts. In their research, native E. coli strains were modified to express both bacterial and eukaryotic genes, leading to successful engraftment in the intestine and the ability to induce functional changes that can reverse disease pathology. This approach not only facilitates the study of specific microbial activities within the gut microbiome but also enhances the potential of live bacterial therapeutics to provide long-lasting benefits and curative effects for patients suffering from various health conditions.

United States

Endure Biotherapeutics (“Endure Bio” ™) in San Diego, California, was founded by Professor Amir Zarrinpar MD, PhD, at the Zarrinpar Laboratory, UCSD.  The company is developing engineered engraftable live biotherapeutics for gastrointestinal diseases by genetically engineering man’s native bacteria to express therapeutic compounds (such as anti-inflammatory cytokines).  Unlike other GI focused microbiome companies, our biotherapeutics will be targeted to remain resident, delivering potentially curative solutions that endure the host environment.

Endure Biotherapeutics

Company Details